Arvinas Inc. Insider Trading

ARVN

⊜ Compare

Last 12 months

Insiders bought 268K and sold $1.42M on the open market.

5% of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$1.15M

1 buy · 19 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 6

executives and directors

Last open-market buy

Mar 2026

Mar 6, 2026

Get an email when ARVN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 24	Andrew Saik Chief Financial Officer	Sold10b5-1 plan	5,696	$8.16	46K	2.9%	Form 4
Jun 17	Angela M Cacace Chief Scientific Officer	Sold10b5-1 plan	2,576	$7.60	20K	1.4%	Form 4
May 21	Randy Teel President and CEO	SoldNo plan	2,209	$9.04	20K	0.8%	Form 4
May 11	Andrew Saik Chief Financial Officer	SoldNo plan	11,139	$9.94	111K	5.5%	Form 4
May 11	David K Loomis VP, Chief Accounting Officer	SoldNo plan	1,919	$9.94	19K	4.6%	Form 4
May 11	Angela M Cacace Chief Scientific Officer	SoldNo plan	9,657	$9.94	96K	5.0%	Form 4
May 11	Noah Berkowitz Chief Medical Officer	SoldNo plan	11,108	$9.94	110K	5.5%	Form 4
May 11	Randy Teel President and CEO	SoldNo plan	9,657	$9.94	96K	3.3%	Form 4
Mar 18	Noah Berkowitz Chief Medical Officer	SoldNo plan	6,435	$11.10	71K	3.1%	Form 4
Mar 6	Briggs Morrison Director	Bought	20,000	$13.40	268K	26%	Form 4
Feb 27	John G Houston Director	SoldNo plan 3 parts	35,297	$13.21 average	466K	3.0%	Form 4
Feb 23	David K Loomis Chief Accounting Officer	SoldNo plan	1,108	$12.16	13K	3.6%	Form 4
Feb 23	Angela M Cacace Chief Scientific Officer	SoldNo plan 2 parts	3,609	$12.16 average	44K	2.4%	Form 4
Feb 23	Randy Teel President and CEO	SoldNo plan 2 parts	4,786	$12.16 average	58K	3.1%	Form 4
Feb 13	Randy Teel President and CEO	SoldNo plan	4,403	$11.89	52K	2.8%	Form 4
Feb 13	Andrew Saik Chief Financial Officer	SoldNo plan	5,134	$11.89	61K	3.1%	Form 4
Feb 13	Angela M Cacace Chief Scientific Officer	SoldNo plan	4,592	$11.89	55K	2.9%	Form 4
Feb 13	Noah Berkowitz Chief Medical Officer	SoldNo plan	5,685	$11.89	68K	3.4%	Form 4
Feb 13	David K Loomis Chief Accounting Officer	SoldNo plan	1,016	$11.89	12K	3.2%	Form 4
Nov 7, 2025	David K Loomis Chief Accounting Officer	SoldNo plan	230	$9.89	2K	0.7%	Form 4
Sep 22, 2025	Briggs Morrison Director	Bought	30,000	$7.57	227K	65%	Form 4
Jun 24, 2025	Andrew Saik Chief Financial Officer	SoldNo plan	5,700	$7.61	43K	3.4%	Form 4
Jun 17, 2025	Angela M Cacace Chief Scientific Officer	SoldNo plan	2,583	$7.49	19K	1.6%	Form 4
Mar 18, 2025	Noah Berkowitz Chief Medical Officer	SoldNo plan	8,658	$8.59	74K	7.3%	Form 4
Feb 24, 2025	David K Loomis Chief Accounting Officer	SoldNo plan	1,214	$16.75	20K	6.0%	Form 4
Feb 24, 2025	Angela M Cacace Chief Scientific Officer	SoldNo plan 2 parts	4,207	$16.70 average	70K	4.1%	Form 4
Feb 24, 2025	Ian Taylor President, R&D	SoldNo plan 2 parts	9,020	$16.71 average	151K	5.4%	Form 4
Feb 24, 2025	John G Houston President and CEO	SoldNo plan 2 parts	31,338	$16.72 average	524K	2.6%	Form 4
Nov 7, 2024	David K Loomis Chief Accounting Officer	SoldNo plan	231	$27.69	6K	2.8%	Form 4

Jun 2410b5-1 plan
Andrew Saik
Chief Financial Officer · sold 5,696 at $8.16
46K
2.9% of stake
Jun 1710b5-1 plan
Angela M Cacace
Chief Scientific Officer · sold 2,576 at $7.60
20K
1.4% of stake
May 21No plan
Randy Teel
President and CEO · sold 2,209 at $9.04
20K
0.8% of stake
May 11No plan
Andrew Saik
Chief Financial Officer · sold 11,139 at $9.94
111K
5.5% of stake
May 11No plan
David K Loomis
VP, Chief Accounting Officer · sold 1,919 at $9.94
19K
4.6% of stake
May 11No plan
Angela M Cacace
Chief Scientific Officer · sold 9,657 at $9.94
96K
5.0% of stake
May 11No plan
Noah Berkowitz
Chief Medical Officer · sold 11,108 at $9.94
110K
5.5% of stake
May 11No plan
Randy Teel
President and CEO · sold 9,657 at $9.94
96K
3.3% of stake
Mar 18No plan
Noah Berkowitz
Chief Medical Officer · sold 6,435 at $11.10
71K
3.1% of stake
Mar 6
Briggs Morrison
Director · bought 20,000 at $13.40
268K
26% of stake
Feb 27No plan
John G Houston
Director · sold 35,297 at avg $13.21
466K
3.0% of stake
Feb 23No plan
David K Loomis
Chief Accounting Officer · sold 1,108 at $12.16
13K
3.6% of stake
Feb 23No plan
Angela M Cacace
Chief Scientific Officer · sold 3,609 at avg $12.16
44K
2.4% of stake
Feb 23No plan
Randy Teel
President and CEO · sold 4,786 at avg $12.16
58K
3.1% of stake
Feb 13No plan
Randy Teel
President and CEO · sold 4,403 at $11.89
52K
2.8% of stake
Feb 13No plan
Andrew Saik
Chief Financial Officer · sold 5,134 at $11.89
61K
3.1% of stake
Feb 13No plan
Angela M Cacace
Chief Scientific Officer · sold 4,592 at $11.89
55K
2.9% of stake
Feb 13No plan
Noah Berkowitz
Chief Medical Officer · sold 5,685 at $11.89
68K
3.4% of stake
Feb 13No plan
David K Loomis
Chief Accounting Officer · sold 1,016 at $11.89
12K
3.2% of stake
Nov 7, 2025No plan
David K Loomis
Chief Accounting Officer · sold 230 at $9.89
2K
0.7% of stake
Sep 22, 2025
Briggs Morrison
Director · bought 30,000 at $7.57
227K
65% of stake
Jun 24, 2025No plan
Andrew Saik
Chief Financial Officer · sold 5,700 at $7.61
43K
3.4% of stake
Jun 17, 2025No plan
Angela M Cacace
Chief Scientific Officer · sold 2,583 at $7.49
19K
1.6% of stake
Mar 18, 2025No plan
Noah Berkowitz
Chief Medical Officer · sold 8,658 at $8.59
74K
7.3% of stake
Feb 24, 2025No plan
David K Loomis
Chief Accounting Officer · sold 1,214 at $16.75
20K
6.0% of stake
Feb 24, 2025No plan
Angela M Cacace
Chief Scientific Officer · sold 4,207 at avg $16.70
70K
4.1% of stake
Feb 24, 2025No plan
Ian Taylor
President, R&D · sold 9,020 at avg $16.71
151K
5.4% of stake
Feb 24, 2025No plan
John G Houston
President and CEO · sold 31,338 at avg $16.72
524K
2.6% of stake
Nov 7, 2024No plan
David K Loomis
Chief Accounting Officer · sold 231 at $27.69
6K
2.8% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ARVN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ARVN

CompareIntrinsic value

HROWHarrow Inc.

$28.75+0.74%46

PHATPhathom Pharmaceuticals Inc.

$5.68-1.05%10

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

PTGXProtagonist Therapeutics Inc.

$143.37+2.23%54

SNDXSyndax Pharmaceuticals Inc.

$10.45-26.87%0

SDGRSchrodinger, Inc.

$28.52+4.93%36

LGNDLigand Pharmaceuticals Inc.

$316.13+0.83%36

RYTMRhythm Pharmaceuticals Inc.

$110.68+28.04%40

Held by ETFs

ARVN is in 29 US ETFs. The largest of them, with ARVN's weight in each:

Spot a number that looks wrong? Check it in ARVN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ARVN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.